DESTINY-Breast02: T-DXd in HER2+ metastatic breast cancer previously treated with T-DM1 VJOncology 1:08 1 year ago 159 Скачать Далее
DESTINY-Breast02: high levels of efficacy of T-DXd in previously treated HER2+ breast cancer VJOncology 3:09 1 year ago 107 Скачать Далее
Updated results of DESTINY-Breast03: T-DXd vs T-DM1 in metastatic HER2+ breast cancer VJOncology 1:20 1 year ago 623 Скачать Далее
Updated survival results of DESTINY-Breast03: T-DXd vs T-DM1 in HER2+ metastatic breast cancer VJOncology 1:08 1 month ago 95 Скачать Далее
Updated findings of T-DXd in DESTINY-Breast02 at ESMO Breast 2024 VJOncology 3:06 2 months ago 165 Скачать Далее
DESTINY-Breast03: T-DXd is superior to T-DM1 in HER2+ metastatic breast cancer VJOncology 2:48 2 years ago 491 Скачать Далее
T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previo... ecancer 7:12 1 year ago 85 Скачать Далее
Choosing between tucatinib and T-DXd in HER2+ breast cancer VJOncology 1:46 2 years ago 554 Скачать Далее
DESTINY-Gastric02: T-Dxd as a second-line treatment for HER2-positive gastric cancer VJOncology 1:58 2 years ago 355 Скачать Далее
Highlights on T-DXd in pretreated HER2-expressing solid tumours : The DESTINY-PanTumor02 study European Society for Medical Oncology (ESMO) 2:38 9 months ago 1 047 Скачать Далее
Trastuzumab deruxtecan shows benefit across HER2+ metastatic breast cancer subgroups ecancer 5:09 2 years ago 998 Скачать Далее
#ESMO21 Expert Video Report on HER2-positive metastatic breast cancer European Society for Medical Oncology (ESMO) 7:30 2 years ago 1 367 Скачать Далее
Trastuzumab deruxtecan vs trastuzumab emtansine in patients with HER2+ metastatic breast cancer ecancer 12:47 2 years ago 890 Скачать Далее
SABCS 2022: Primary results of the randomized, phase 3 study DESTINY-Breast02 + Q & A Oncoletter 11:35 1 year ago 272 Скачать Далее
TUXEDO-1: T-DXd for patients with HER2-positive breast cancer and brain metastasis VJOncology 0:53 2 years ago 320 Скачать Далее
